The purpose of the study is to find out if depemokimab works better than placebo in treating people with this lung disease who have a type of inflammation called Type 2 inflammation. The study will look at whether the medication can reduce the number of times symptoms suddenly get worse, which doctors call exacerbations. These are times when breathing problems become much worse and may need treatment with antibiotics or steroid pills, or sometimes even a visit to the emergency room or hospital.

During the study, people will receive treatment for up to 104 weeks, which is about two years. The doctors will check how often breathing problems get worse, how long it takes before problems get worse, and how the disease affects daily life and breathing symptoms. The study will compare results between people receiving depemokimab and those receiving placebo to see if the medication helps reduce flare-ups and improves quality of life for people with this lung condition.

The main goal is to see if the drug can bring the level of cortisol measured in urine back to normal. The trial is double‑blind, meaning neither the participants nor the doctors know who gets the real medicine, and it lasts about 30 weeks. People are randomly assigned to one of the two groups and take a tablet each day.

During the study, participants will provide urine samples to measure urinary‑free cortisol, have their blood pressure checked regularly, and may undergo a sugar‑drink test (OGTT) to look at how their body handles glucose. These checks help researchers understand how well the treatment works and whether any side effects appear. The study involves several clinic visits, simple tests, and daily medication taken at home.

The purpose of the study is to determine whether the investigational drug reduces the severity of the movements compared with the placebo. Participants will be randomly assigned to one of the two groups and will take the assigned capsule each day for about eight weeks, with regular clinic visits to record any changes and to monitor safety.

Effectiveness will be assessed using the Abnormal Involuntary Movement Scale (AIMS), a video‑based rating that scores the level of involuntary movements, and the Clinical Global Impression – Improvement (CGI-I), a simple overall rating of how much a person’s condition has improved. Both scales are reviewed by experts who do not know which treatment was given. Safety checks, such as blood tests and reports of side effects, will also be performed throughout the study.

The purpose of the study is to evaluate the safety, tolerability, and effect of the medication on the activity of a clot‑helping protein known as Factor XI after eight weeks. Participants will receive a few injections over several weeks and will attend brief visits for simple check‑ups, including blood tests and basic heart monitoring, to track any side effects and how the drug behaves in the body.

The purpose of this study is to continue providing treatment to patients who have completed a previous cancer study with Durvalumab and are still benefiting from it, according to their doctor. The study will monitor the safety and how well patients tolerate the treatment. In addition to Durvalumab, the study may also involve other medications such as Infliximab and Mycophenolate Mofetil, which are used for different purposes. Infliximab is administered through an infusion, while Mycophenolate Mofetil is taken orally in capsule form.

Participants in this study will continue to receive their treatment as long as they are benefiting from it. The study will keep track of any serious side effects that occur up to 90 days after the last dose of the study treatment. This trial aims to ensure that patients who are doing well on their current treatment can continue to receive it safely.

Participants are randomly assigned to receive either belumosudil tablets taken by mouth or one of the comparator medicines chosen by their doctor. The study lasts about 24 weeks, during which regular clinic visits are scheduled to check symptoms, perform blood tests, and assess overall health. Researchers look at the overall response rate, which means the percentage of people whose disease shows improvement, using standard doctor‑approved guidelines (NIH consensus response criteria). Systemic therapy refers to medicines that work throughout the whole body, and any need for new systemic treatment, relapse of the underlying disease, or death is recorded.

Throughout the trial, safety is closely monitored; blood samples are taken to measure drug levels and to watch for side effects. Participants can stop the study at any time if they experience problems. The information gathered will help determine whether belumosudil works better and is safe for people with this condition.

The main goal of the study is to see if the injectable letrozole works better than the oral Femara when both are given with ribociclib. Participants will be randomly assigned to one of the two treatment groups and will take the study medicines for several months, with regular check‑ups to monitor how the cancer is responding and to watch for side effects. The study does not involve any surgical procedures; all medicines are taken by mouth or by a simple injection into the muscle.

After the first dose, participants will return for clinic visits every few weeks during the first few months, then roughly every two to three months for the rest of the study. At each visit doctors will ask about symptoms, perform basic physical exams, and may order imaging tests such as scans to see if the cancer has grown or shrunk. The study continues until the cancer progresses, unacceptable side effects occur, or the participant chooses to stop.

The purpose of the trial is to evaluate the clinical efficacy of frevecitinib. Over a period of about three months, participants will take the study medication each day and attend clinic visits at the start of the study and at weeks 2, 4, 8 and 12. During these visits lung function will be measured using tests such as FEV1, which records how much air can be forced out of the lungs in one second, and symptom questionnaires will be completed.

Safety will be monitored throughout the study with regular checks of blood tests, heart rhythm recordings (ECG), blood pressure, and reports of any adverse events. Participants will continue their regular asthma inhalers while using the study powder, and any changes in rescue inhaler use or asthma symptoms will be recorded.

Participants are randomly assigned to receive either the study drug or placebo on a regular schedule for several months. Throughout the trial, blood tests are performed to measure thyroid hormones (such as T3, T4, and TSH) and antibodies that affect the thyroid (TRAb). Researchers also monitor overall health, side effects, and quality of life using questionnaires. The study follows participants for up to 24 weeks to see how many can maintain normal thyroid function without antithyroid drugs and to assess any safety concerns associated with the treatment.

The purpose of the trial is to determine whether daily treatment with Engasertib reduces the frequency of epistaxis compared with placebo over a period of about 28 weeks. Participants will receive either the study drug or placebo each day, keep a simple diary to record each nosebleed event, and attend regular clinic visits where basic health checks and blood work are performed to monitor safety. The study is conducted in a double-blind manner, meaning that neither the participants nor the study staff know which treatment is being taken, which helps ensure unbiased results.

The purpose of this study is to evaluate how well XmAb942 works in helping people with moderately to severely active Ulcerative Colitis achieve clinical remission, which means bringing the disease under control so that symptoms improve significantly. The study is divided into two parts. The first part tests the medication in healthy volunteers to check its safety. The second part involves people who have moderate to severe Ulcerative Colitis and have not responded well to previous treatments, lost response to them, or could not tolerate them. Participants in the second part must have had Ulcerative Colitis for at least three months and show active disease with inflammation visible during examination of the bowel.

During the study, participants will be randomly assigned to receive either XmAb942 or placebo. The treatment period lasts up to 48 weeks, with an important assessment at week 12 to see if the medication is working. Doctors will measure improvement by looking at various signs of the disease, including bleeding, bowel movement frequency, and inflammation seen during bowel examination. The study will also monitor any side effects or unwanted reactions that occur during treatment to ensure the safety of participants.

During the trial, volunteers will receive the assigned injection at regular visits over several months. At each visit, doctors will check the skin’s condition and the level of itching using simple scales. One of the scales, called the EASI score, measures how much of the body is affected and how severe the rash is. Another assessment, the vIGA-AD, looks at overall disease activity, while the PP-NRS records how strongly the patient feels the itch each day. These checks help determine whether the medication improves the skin and reduces itching compared with the placebo.

The purpose of the study is to see how well Concizumab works in preventing bleeding episodes compared to the previous treatment the children were receiving. The study will involve children who have not used Concizumab before. Participants will receive regular injections of Concizumab over a period of time, and the number of bleeding episodes they experience will be monitored and compared to their previous treatment.

Throughout the study, researchers will also keep track of any side effects or reactions to the medication, such as injection site reactions or the development of antibodies against Concizumab. The study aims to provide valuable information on the safety and effectiveness of Concizumab in managing bleeding episodes in young children with hemophilia.

During the 24‑week period, participants are randomly assigned to one of the two groups and neither the participants nor the study staff know which treatment is given (double‑blind). Regular visits include blood tests that measure NT-proBNP, a protein that rises when the heart is under stress, and imaging tests such as an ultrasound of the heart (echocardiogram) that assess measurements like left ventricular end-diastolic volume index, left ventricular end-systolic volume index, E/e′ ratio, global longitudinal strain and left atrial volume index. Participants also complete the Kansas City cardiomyopathy questionnaire to report symptoms and quality of life, and a routine 12‑lead Electrocardiogram is performed to check the heart’s electrical activity. Throughout the study, safety is monitored by recording any side effects and checking routine laboratory values.

The study will use different combinations of these medications. Some participants will receive both mirikizumab and tirzepatide, while others will receive mirikizumab and a placebo. Both medications are given as injections under the skin, except in some cases where mirikizumab may be given through a vein. The treatment will continue for 52 weeks, which is approximately one year.

The study will measure how well the medications work together to achieve three main goals: reducing Crohn’s Disease symptoms, healing the inside of the digestive tract, and helping participants lose weight. The amount of tirzepatide used in the study may be adjusted up to 15 milligrams, depending on how well it is tolerated.

The treatment being studied involves a combination of two medications: MK-1084 and pembrolizumab. Pembrolizumab is also known by the brand name KEYTRUDA and is given as an infusion, which means it is delivered directly into the bloodstream through a vein. MK-1084 is taken as a tablet. Some participants in the study will receive pembrolizumab with MK-1084, while others will receive pembrolizumab with a placebo, which looks like the real medication but does not contain any active ingredients. The purpose of the study is to compare the effectiveness of these two treatment combinations.

Participants in the study will receive their assigned treatment and will be monitored over a period of time to see how their cancer responds. The study will look at how long participants live without their cancer getting worse, known as progression-free survival, and overall survival, which is the length of time participants live after starting the treatment. The study will also track any side effects experienced by participants and how the treatment affects their quality of life. This information will help researchers understand the potential benefits and risks of the new treatment combination for people with this specific type of lung cancer.

Participants are randomly assigned to receive either the test drug or placebo for about three months, and neither the participants nor the study staff know which treatment is given, a design known as double-blind. After the initial 12‑week period, the study continues for an additional 40 weeks in a phase where participants may switch to other antipsychotic medications or continue the study drug, using a “double‑dummy” approach to keep the blind intact. Throughout the trial, safety checks and simple questionnaires are performed at regular visits to monitor how participants feel and whether any problems develop.

The purpose of the study is to determine whether oral semaglutide leads to greater weight loss compared with the placebo when combined with diet and exercise. Participants will take the assigned tablet every day for several months, attend regular clinic visits where their weight, waist size, blood pressure, and blood tests are checked, and report any side effects. The study will track changes in body weight and related health measures over the course of the trial.

The purpose of the study is to determine whether the experimental drug can restore a normal heart rhythm, known as sinus rhythm. In the trial, adult participants are randomly assigned to receive either the study drug or the placebo. The assigned treatment is delivered by a short intravenous infusion, and participants are observed for at least three hours to see if their heart rhythm changes from the irregular pattern to a steady one without needing additional procedures. Safety checks are performed throughout the visit, and a blood sample is taken at the end of the infusion to measure how much of the medicine is present in the body.

Participants will be randomly assigned to receive either elecoglipron at one of two dose levels or the placebo, while continuing their usual insulin therapy. Over about 40 weeks, they will visit the clinic several times for simple blood tests, including a test called HbA1c that shows the average blood sugar level over the past few months. The study will also check changes in body weight and blood pressure, but no detailed procedures are described here.

The purpose of the trial is to determine whether AZD8965 can reduce the loss of lung function compared with placebo, using the change in FVC (forced vital capacity, the amount of air exhaled forcefully after a deep breath) as the main measure over about 24 weeks. Participants will be screened, then randomly assigned to receive either the study drug or placebo for a six‑month period, with regular clinic visits for safety checks, blood samples, and simple breathing tests. Throughout the study, any side effects and overall health will be closely monitored.

The main goal of the study is to see whether the new combination works better and is safe compared with the single drug. Participants will receive their assigned injection at regular visits over about one year, and they will come to the clinic for check‑ups, blood tests, and questionnaires about symptoms. The study is double‑blind, meaning neither the participants nor the doctors know which treatment is being given, to keep the results unbiased.

The key result the researchers are looking for is clinical remission at week 48, which means the person’s symptoms have cleared enough that they no longer need daily medication for the disease. Throughout the trial, safety will be monitored by checking for any side effects or changes in health.

The purpose of the study is to determine whether nerandomilast can more effectively delay death or disease worsening compared with the placebo.

Participants will be randomly assigned to receive either the active medication or the placebo for about one year. During this time, they will attend regular clinic visits where doctors will check skin thickness, lung function (including a test called FVC that measures how much air can be forced out of the lungs), physical ability, and overall health. The study will track any serious health events, changes in symptoms, and overall survival throughout the treatment period.